SCHEMBL25829763

SCHEMBL25829763

CC(C)(C)OC(=O)Nc1cc(F)c([Si](C)(C)C)c(F)c1F

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 2/20 0.42
RXFP1 Q9HBX9 1/20 0.37
BRAF P15056 1/20 0.37
KCNQ4 P56696 1/20 0.36
KCNQ5 Q9NR82 1/20 0.36
BRD9 Q9H8M2 1/20 0.36
SYK P43405 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA9 Q16790 1/20 0.34
PSMB8 P28062 1/20 0.34
METAP1 P53582 1/20 0.34
P2RX3 P56373 2/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
AAK1 Q2M2I8 2/20 0.34
ATR Q13535 1/20 0.33
EGLN2 Q96KS0 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6124200 0.83 CYP17A1 (0.43) CYP17A1RXFP1BRAFKCNQ4KCNQ5
SCHEMBL25863098 0.81 CYP17A1 (0.42) CYP17A1RXFP1BRAFKCNQ4KCNQ5
SCHEMBL25829859 0.79 CYP17A1 (0.41) CYP17A1RXFP1BRAFKCNQ4KCNQ5
SCHEMBL25829310 0.79 CYP17A1 (0.41) CYP17A1RXFP1BRAFKCNQ4KCNQ5
SCHEMBL25262833 0.79 TSHR (0.34) POLB
SCHEMBL4621173 0.78 CYP17A1 (0.42) CYP17A1RXFP1BRAFKCNQ4KCNQ5
SCHEMBL14725520 0.77 CYP17A1 (0.48) CYP17A1RXFP1BRAFKCNQ4KCNQ5
SCHEMBL29932328 0.77 CYP17A1 (0.41) CYP17A1RXFP1BRAFKCNQ4KCNQ5
SCHEMBL29021616 0.77 CYP17A1 (0.41) CYP17A1RXFP1BRAFKCNQ4KCNQ5
SCHEMBL25830504 0.76 CYP17A1 (0.39) CYP17A1RXFP1BRAFKCNQ4KCNQ5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234922-A1 PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID ENANTA PHARMACEUTICALS, INC. 2023-07-27 US disclosed
US-20230234922-A1 PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID ENANTA PHARMACEUTICALS, INC. 2023-07-27 US disclosed
US-20230234922-A1 PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID ENANTA PHARMACEUTICALS, INC. 2023-07-27 US disclosed
WO-2023137007-A1 PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID ENANTA PHARMACEUTICALS, INC. (US) 2023-07-20 WO disclosed
WO-2023137007-A1 PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID ENANTA PHARMACEUTICALS, INC. (US) 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234922-A1 PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID ACE2, HTR3C, SARS1 CYP17A1 476/4885RXFP1 3765/4885BRAF 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.